Literature DB >> 12169391

The anti-tumor activities of interferon (IFN)-alpha in chronic myelogenous leukaemia (CML)-derived cell lines depends on the IFN-alpha subtypes.

Yoshiaki Yanai1, Osamu Sanou, Kouzou Yamamoto, Hiroshi Yamauchi, Hakuo Ikegami, Masashi Kurimoto.   

Abstract

Here we report on the anti-tumor effects of five interferon (IFN)-alpha subtypes, alpha1, alpha2, alpha5, alpha8, and alpha10 in chronic myelogenous leukaemia (CML)-derived cell lines. All of the CML cells can respond to IFN-alpha although the anti-tumor effects of IFN-alpha depend on the target cell and on the type of IFN-alpha subtype used. Proliferation assays showed that IFN-alpha8 was substantially more effective than the other four IFN-alpha subtypes. IFN-alpha8 was the most potent at upregulating immunomodulatory molecule expression while IFN-alpha1 was least potent. These data indicate in vitro distinctions between IFN-alpha subtypes that should be appreciated more in the clinic.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12169391     DOI: 10.1016/s0304-3835(02)00277-x

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

1.  Effects of interferon-alpha subtypes on the TH1/TH2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders.

Authors:  Toshio Ariyasu; Takeshi Tanaka; Noboru Fujioka; Yoshiaki Yanai; Shigeto Yamamoto; Hiroshi Yamauchi; Hakuo Ikegami; Masao Ikeda; Masashi Kurimoto
Journal:  In Vitro Cell Dev Biol Anim       Date:  2005 Jan-Feb       Impact factor: 2.416

2.  The differential activity of interferon-α subtypes is consistent among distinct target genes and cell types.

Authors:  Herwig P Moll; Thomas Maier; Anna Zommer; Thomas Lavoie; Christine Brostjan
Journal:  Cytokine       Date:  2010-10-12       Impact factor: 3.861

3.  Differential activity of interferon-α8 promoter is regulated by Oct-1 and a SNP that dictates prognosis of glioma.

Authors:  Gary Kohanbash; Eiichi Ishikawa; Mitsugu Fujita; Maki Ikeura; Kayla McKaveney; Jianzhong Zhu; Masashi Sakaki; Saumendra N Sarkar; Hideho Okada
Journal:  Oncoimmunology       Date:  2012-07-01       Impact factor: 8.110

4.  Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists.

Authors:  Woubalem Birmachu; Raymond M Gleason; Barbara J Bulbulian; Christie L Riter; John P Vasilakos; Kenneth E Lipson; Yuri Nikolsky
Journal:  BMC Immunol       Date:  2007-10-12       Impact factor: 3.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.